Biosimilar developer Celltrion has seen strong success with its biosimilar infliximab, CT-P13, which is marketed in the United States as Inflectra and in other territories as Remsima. This week, the company said that its product has captured 56% of the infliximab market in Europe as of the third quarter of 2018.
Biosimilar developer Celltrion has seen strong success with its biosimilar infliximab, CT-P13, which is marketed in the United States as Inflectra and in other territories as Remsima. This week, the company said that its product has captured 56% of the infliximab market in Europe as of the third quarter of 2018.
That number was reported by Celltrion’s chairman, Jung-Jin Seo, during his presentation at the 37th Annual J.P. Morgan Healthcare Conference held January 7-10 in San Francisco, California. Looking to the future, Hyoung-Ki Kim, Celltrion’s vice chairman, added in a statement that the development of the as-yet unapproved subcutaneously administered version of the product, which has the potential to give patients an alternative to regular infusions and reduce infusion-related costs, will be a key focus of the company in 2019.
According to Celltrion, a launch of the subcutaneous CT-P13 product could bring the total value of the biosimilar infliximab market from $9.2 billion in 2019 to $42.8 billion in 2020.
The European Medicines Agency is currently reviewing the proposed formulation, having accepted an extension marketing authorization application for review in December 2018. Celltrion’s data package for the formulation includes results from a phase 3 clinical trial, results of which were reported at the 2018 European League Against Rheumatism's Annual European Congress of Rheumatology. The study’s investigators reported that the subcutaneous formulation had similar efficacy and generally similar safety to the currently approved intravenous product in patients with rheumatoid arthritis.
Separately, Celltrion revealed positive results from a phase 1 study comparing the subcutaneous formulation to the approved formulation in patients with Crohn's disease, and the researchers found that pharmacokinetic and pharmacodynamic modeling based on the comparable efficacy and safety results in the study suggest that the subcutaneous and intravenous doses of CT-P13 are similar.
If Celltrion is successful in securing a marketing authorization for this formulation of its product, the company will the sole developer—whether innovator or biosimilar—to market a subcutaneous infliximab option.
Celltrion also highlighted its success with CT-P10, its rituximab biosimilar authorized in the US and EU markets as Truxima. While the biosimilar has not yet launched in the United States, it has, said Celltrion, captured 35% of the share for the rituximab market in 16 European countries as of the third quarter of 2018. In the so-called “EU 5”—the United Kingdom, Germany, France, Italy, and Spain—the biosimilar has reached 36% market share.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.